Gary Horwith
Impact in
- Infectious Diseases top 1%
- Antifungal resistance and susceptibility
- Antimicrobial Resistance in Staphylococcus
- Microbiology top 5%
Papers in
-
- Antimicrobial Resistance in Staphylococcus 5
- Antifungal resistance and susceptibility 3
-
- Cancer therapeutics and mechanisms 3
- Co-authors
- Ali Fattom (4 shared papers)Robert Naso (5 shared papers)Steve Fuller (3 shared papers)Nita L. Seibel (1 shared paper)John W. Hiemenz (1 shared paper)Jeffrey L. Silber (1 shared paper)John R. Perfect (1 shared paper)Lily Lee (1 shared paper)
- Journals
- Vaccine (4 papers)Antimicrobial Agents and Chemotherapy (2 papers)Nicotine & Tobacco Research (1 paper)Clinical Infectious Diseases (1 paper)Clinical Pharmacology & Therapeutics (1 paper)
- Partner nations
- United StatesIsraelCameroon
In The Last Decade
Gary Horwith
18 papers receiving 1.5k citations
Gary Horwith's Hit Papers
Peers
Comparison fields: 5 of 99
- Infectious Diseases 993
- Microbiology 125
- Epidemiology 583
- Clinical Biochemistry 108
- Applied Microbiology and Biotechnology 17
Countries citing papers authored by Gary Horwith
This map shows the geographic impact of Gary Horwith's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gary Horwith with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gary Horwith more than expected).
Fields of papers citing papers by Gary Horwith
This network shows the impact of papers produced by Gary Horwith. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gary Horwith. The network helps show where Gary Horwith may publish in the future.
Co-authors
The 25 scholars most cited alongside Gary Horwith, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | Amphotericin B Lipid Complex for Invasive Fungal Infections: Analysis of Safety and Efficacy in 556 Cases Hit paper breakdown → | 1998 | 513 |
| 2 | 2002 | 395 | |
| 3 | 2005 | 155 | |
| 4 | 2003 | 138 | |
| 5 | 2004 | 77 | |
| 6 | 1997 | 77 | |
| 7 | 1992 | 51 | |
| 8 | Protective and restorative role of AS101 in combination with chemotherapy. | 1991 | 50 |
| 9 | 2000 | 40 | |
| 10 | 2008 | 40 | |
| 11 | 2005 | 35 | |
| 12 | 2004 | 33 | |
| 13 | 2020 | 16 | |
| 14 | Use and mechanism of action of AS101 in protecting bone marrow colony forming units-granulocyte-macrophage following purging with ASTA-Z 7557. | 1991 | 14 |
| 15 | 2020 | 9 | |
| 16 | 2022 | 4 | |
| 17 | Phase 1 Safety and Pharmacokinetics of SQ109, a new diamine anti-tuberculosis drug | 2007 | 2 |
| 18 | 2004 | 2 |
About Gary Horwith
Gary Horwith is a scholar working on Infectious Diseases, Molecular Biology, Epidemiology, Immunology and Oncology, having authored 18 papers that have together received 1.7k indexed citations. Recurring topics across this work include Antimicrobial Resistance in Staphylococcus (5 papers), Antifungal resistance and susceptibility (3 papers), Cancer therapeutics and mechanisms (3 papers), Hepatitis B Virus Studies (2 papers), Fungal Infections and Studies (2 papers), Essential Oils and Antimicrobial Activity (2 papers), Radiation Therapy and Dosimetry (1 paper) and T-cell and B-cell Immunology (1 paper). The work is most often cited by research in Infectious Diseases (993 citations), Microbiology (125 citations), Epidemiology (583 citations), Clinical Biochemistry (108 citations) and Applied Microbiology and Biotechnology (17 citations). Gary Horwith has collaborated with scholars based in United States, Israel and Cameroon. Frequent co-authors include Ali Fattom, Robert Naso, Steve Fuller, Nita L. Seibel, John W. Hiemenz, Jeffrey L. Silber, John R. Perfect, Lily Lee, Mark J. DiNubile and Annette C. Reboli. Their work appears in journals such as Vaccine, Antimicrobial Agents and Chemotherapy, Nicotine & Tobacco Research, Clinical Infectious Diseases and Clinical Pharmacology & Therapeutics.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.